Accessibility Menu
Nuvation Bio Stock Quote

Nuvation Bio (NYSE: NUVB)

$4.21
(13.6%)
+0.51
Price as of October 21, 2025, 3:57 p.m. ET

KEY DATA POINTS

Current Price
$4.21
Daily Change
(13.6%) +$0.51
Day's Range
$3.66 - $4.21
Previous Close
$3.7
Open
$3.68
Beta
1.30
Volume
11,949,289
Average Volume
6,090,753
Market Cap
1.3B
Market Cap / Employee
$3.70M
52wk Range
$1.54 - $4.21
Revenue
-
Gross Margin
0.20%
Dividend Yield
N/A
EPS
-$0.63
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Nuvation Bio Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
NUVB+48.59%-65.34%-19.1%-62%
S&P+14.84%+96.04%+14.41%+94%

Nuvation Bio Company Info

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$4.83M236.8%
Gross Profit$1.90M1318.6%
Gross Margin39.33%50.2%
Market Cap$663.51M-8.4%
Market Cap / Employee$3.02M0.0%
Employees220331.4%
Net Income-$59.01M87.2%
EBITDA-$63.23M-40.3%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$247.97M623.3%
Accounts Receivable$2.69M2201.7%
Inventory0.60.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$193.15M-30.0%
Short Term Debt$10.21M-25.5%

Ratios

Q2 2025YOY Change
Return On Assets-32.67%50.0%
Return On Invested Capital-36.30%-21.5%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$48.36M-29.6%
Operating Free Cash Flow-$48.18M-29.1%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book2.211.781.281.5846.71%
Price to Sales289.76113.8454.3946.29-90.71%
Price to Tangible Book Value2.241.791.291.6048.26%
Enterprise Value to EBITDA-1.85-7.49-2.48-4.11-56.59%
Return on Equity-95.5%-106.3%-119.7%-64.4%-44.40%
Total Debt$11.19M$8.92M$11.41M$203.37M-29.78%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.